{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:33:24Z","timestamp":1790775204103,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la recherche m\u00e9dicale","doi-asserted-by":"crossref","award":["DQ20170336751"],"award-info":[{"award-number":["DQ20170336751"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-RHUS-0012"],"award-info":[{"award-number":["ANR-18-RHUS-0012"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00415-021-10870-6","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T13:02:41Z","timestamp":1635339761000},"page":"1701-1714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update"],"prefix":"10.1007","volume":"269","author":[{"given":"Alberto","family":"Vogrig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Mu\u00f1iz-Castrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-3056","authenticated-orcid":false,"given":"Bastien","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"10870_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL et al (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96:754\u2013766. https:\/\/doi.org\/10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"10870_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"key":"10870_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R et al (2020) Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12030738","journal-title":"Cancers (Basel)"},{"key":"10870_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659\u2013669. https:\/\/doi.org\/10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"10870_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA et al (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9:e002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435","journal-title":"J Immunother Cancer"},{"key":"10870_CR6","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755\u20131764. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"10870_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10870_CR8","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1212\/CON.0000000000000873","volume":"26","author":"BD Santomasso","year":"2020","unstructured":"Santomasso BD (2020) Anticancer drugs and the nervous system. Continuum (Minneap Minn) 26:732\u2013764. https:\/\/doi.org\/10.1212\/CON.0000000000000873","journal-title":"Continuum (Minneap Minn)"},{"key":"10870_CR9","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1212\/CON.0000000000000937","volume":"26","author":"EQ Lee","year":"2020","unstructured":"Lee EQ (2020) Neurologic complications in patients with cancer. Continuum (Minneap Minn) 26:1629\u20131645. https:\/\/doi.org\/10.1212\/CON.0000000000000937","journal-title":"Continuum (Minneap Minn)"},{"key":"10870_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.CON.0000413665.80915.c4","volume":"18","author":"AA Pruitt","year":"2012","unstructured":"Pruitt AA (2012) CNS infections in patients with cancer. Continuum (Minneap Minn) 18:384\u2013405. https:\/\/doi.org\/10.1212\/01.CON.0000413665.80915.c4","journal-title":"Continuum (Minneap Minn)"},{"key":"10870_CR11","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.4103\/2152-7806.111304","volume":"4","author":"E Le Rhun","year":"2013","unstructured":"Le Rhun E, Taillibert S, Chamberlain MC (2013) Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 4:S265-288. https:\/\/doi.org\/10.4103\/2152-7806.111304","journal-title":"Surg Neurol Int"},{"key":"10870_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13317-019-0124-6","volume":"11","author":"S Mu\u00f1iz-Castrillo","year":"2020","unstructured":"Mu\u00f1iz-Castrillo S, Vogrig A, Honnorat J (2020) Associations between HLA and autoimmune neurological diseases with autoantibodies. Autoimmun Highlights 11:2. https:\/\/doi.org\/10.1186\/s13317-019-0124-6","journal-title":"Autoimmun Highlights"},{"key":"10870_CR13","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/acn3.51213","volume":"7","author":"H Chang","year":"2020","unstructured":"Chang H, Shin Y-W, Keam B et al (2020) HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor. Ann Clin Transl Neurol 7:2243\u20132250. https:\/\/doi.org\/10.1002\/acn3.51213","journal-title":"Ann Clin Transl Neurol"},{"key":"10870_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","volume":"107","author":"OH Ali","year":"2019","unstructured":"Ali OH, Berner F, Bomze D et al (2019) Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 107:8\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.009","journal-title":"Eur J Cancer"},{"key":"10870_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","volume":"7","author":"G Manson","year":"2019","unstructured":"Manson G, Maria ATJ, Poizeau F et al (2019) Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J Immunother Cancer 7:337. https:\/\/doi.org\/10.1186\/s40425-019-0821-8","journal-title":"J Immunother Cancer"},{"key":"10870_CR16","doi-asserted-by":"publisher","first-page":"175628642093279","DOI":"10.1177\/1756286420932797","volume":"13","author":"A Vogrig","year":"2020","unstructured":"Vogrig A, Mu\u00f1iz-Castrillo S, Desestret V et al (2020) Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Ther Adv Neurol Disord 13:1756286420932797. https:\/\/doi.org\/10.1177\/1756286420932797","journal-title":"Ther Adv Neurol Disord"},{"key":"10870_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","volume":"9","author":"AC Guidon","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9:e002890. https:\/\/doi.org\/10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"key":"10870_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"10870_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000604","volume":"6","author":"A Vogrig","year":"2019","unstructured":"Vogrig A, Fouret M, Joubert B et al (2019) Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 6:e604. https:\/\/doi.org\/10.1212\/NXI.0000000000000604","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10870_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","volume":"91","author":"A Vogrig","year":"2020","unstructured":"Vogrig A, Mu\u00f1iz-Castrillo S, Joubert B et al (2020) Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry 91:772\u2013778. https:\/\/doi.org\/10.1136\/jnnp-2020-323055","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10870_CR21","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00520-005-0825-4","volume":"13","author":"JA Zell","year":"2005","unstructured":"Zell JA, Chang JC (2005) Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer 13:870\u2013877. https:\/\/doi.org\/10.1007\/s00520-005-0825-4","journal-title":"Support Care Cancer"},{"key":"10870_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fmed.2020.00137","volume":"7","author":"M Coureau","year":"2020","unstructured":"Coureau M, Meert A-P, Berghmans T, Grigoriu B (2020) Efficacy and toxicity of immune -checkpoint inhibitors in patients with preexisting autoimmune disorders. Front Med (Lausanne) 7:137. https:\/\/doi.org\/10.3389\/fmed.2020.00137","journal-title":"Front Med (Lausanne)"},{"key":"10870_CR23","doi-asserted-by":"publisher","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","volume":"2","author":"S Shelly","year":"2020","unstructured":"Shelly S, Triplett JD, Pinto MV et al (2020) Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun 2:fcaa181. https:\/\/doi.org\/10.1093\/braincomms\/fcaa181","journal-title":"Brain Commun"},{"key":"10870_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.642800","volume":"12","author":"C Valencia-Sanchez","year":"2021","unstructured":"Valencia-Sanchez C, Zekeridou A (2021) Paraneoplastic neurological syndromes and beyond emerging with the introduction of immune checkpoint inhibitor cancer immunotherapy. Front Neurol 12:642800. https:\/\/doi.org\/10.3389\/fneur.2021.642800","journal-title":"Front Neurol"},{"key":"10870_CR25","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D, David WS, Amato AA et al (2019) Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93:e1093\u2013e1103. https:\/\/doi.org\/10.1212\/WNL.0000000000008091","journal-title":"Neurology"},{"key":"10870_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","volume":"8","author":"S Engelborghs","year":"2017","unstructured":"Engelborghs S, Niemantsverdriet E, Struyfs H et al (2017) Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst) 8:111\u2013126. https:\/\/doi.org\/10.1016\/j.dadm.2017.04.007","journal-title":"Alzheimers Dement (Amst)"},{"key":"10870_CR27","doi-asserted-by":"publisher","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","volume":"96","author":"A Vogrig","year":"2021","unstructured":"Vogrig A, Mu\u00f1iz-Castrillo S, Joubert B et al (2021) Cranial nerve disorders associated with immune checkpoint inhibitors. Neurology 96:e866\u2013e875. https:\/\/doi.org\/10.1212\/WNL.0000000000011340","journal-title":"Neurology"},{"key":"10870_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000701","author":"B D\u00e9chelotte","year":"2020","unstructured":"D\u00e9chelotte B, Mu\u00f1iz-Castrillo S, Joubert B et al (2020) Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000701","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10870_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/WNP.0000000000000475","volume":"35","author":"CR Newey","year":"2018","unstructured":"Newey CR, Kinzy TG, Punia V, Hantus S (2018) Continuous electroencephalography in the critically ill: clinical and continuous electroencephalography markers for targeted monitoring. J Clin Neurophysiol 35:325\u2013331. https:\/\/doi.org\/10.1097\/WNP.0000000000000475","journal-title":"J Clin Neurophysiol"},{"key":"10870_CR30","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1111\/epi.16282","volume":"60","author":"A Vogrig","year":"2019","unstructured":"Vogrig A, Joubert B, Andr\u00e9-Obadia N et al (2019) Seizure specificities in patients with antibody-mediated autoimmune encephalitis. Epilepsia 60:1508\u20131525. https:\/\/doi.org\/10.1111\/epi.16282","journal-title":"Epilepsia"},{"key":"10870_CR31","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","volume":"91","author":"M Touat","year":"2018","unstructured":"Touat M, Maisonobe T, Knauss S et al (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91:e985\u2013e994. https:\/\/doi.org\/10.1212\/WNL.0000000000006124","journal-title":"Neurology"},{"key":"10870_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","volume":"92","author":"A Johansen","year":"2019","unstructured":"Johansen A, Christensen SJ, Scheie D et al (2019) Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology 92:663\u2013674. https:\/\/doi.org\/10.1212\/WNL.0000000000007235","journal-title":"Neurology"},{"key":"10870_CR33","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","volume":"95","author":"E Sechi","year":"2020","unstructured":"Sechi E, Markovic SN, McKeon A et al (2020) Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95:e2442\u2013e2452. https:\/\/doi.org\/10.1212\/WNL.0000000000010632","journal-title":"Neurology"},{"key":"10870_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","volume":"106","author":"A Moreira","year":"2019","unstructured":"Moreira A, Loquai C, Pf\u00f6hler C et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12\u201323. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.033","journal-title":"Eur J Cancer"},{"key":"10870_CR35","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127\u20131134. https:\/\/doi.org\/10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"key":"10870_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jns.2018.01.030","volume":"387","author":"J Bourgeois-Vionnet","year":"2018","unstructured":"Bourgeois-Vionnet J, Joubert B, Bernard E et al (2018) Nivolumab-induced myositis: a case report and a literature review. J Neurol Sci 387:51\u201353. https:\/\/doi.org\/10.1016\/j.jns.2018.01.030","journal-title":"J Neurol Sci"},{"key":"10870_CR37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000494078","volume":"10","author":"Y Nakatani","year":"2018","unstructured":"Nakatani Y, Tanaka N, Enami T et al (2018) Lambert\u2013Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol 10:346\u2013352. https:\/\/doi.org\/10.1159\/000494078","journal-title":"Case Rep Neurol"},{"key":"10870_CR38","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","volume":"11","author":"Y-T Huang","year":"2020","unstructured":"Huang Y-T, Chen Y-P, Lin W-C et al (2020) Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 11:634. https:\/\/doi.org\/10.3389\/fneur.2020.00634","journal-title":"Front Neurol"},{"key":"10870_CR39","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.2169\/internalmedicine.9153-17","volume":"57","author":"A Mitsune","year":"2018","unstructured":"Mitsune A, Yanagisawa S, Fukuhara T et al (2018) Relapsed myasthenia gravis after nivolumab treatment. Intern Med 57:1893\u20131897. https:\/\/doi.org\/10.2169\/internalmedicine.9153-17","journal-title":"Intern Med"},{"key":"10870_CR40","first-page":"107","volume":"28","author":"AS Patel","year":"2019","unstructured":"Patel AS, Snook RJ, Sehdev A (2019) Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients. Discov Med 28:107\u2013111","journal-title":"Discov Med"},{"key":"10870_CR41","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s00415-020-10213-x","volume":"268","author":"K Okada","year":"2021","unstructured":"Okada K, Seki M, Yaguchi H et al (2021) Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. J Neurol 268:680\u2013688. https:\/\/doi.org\/10.1007\/s00415-020-10213-x","journal-title":"J Neurol"},{"key":"10870_CR42","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1212\/01.CON.0000413661.58045.e7","volume":"18","author":"JL Clarke","year":"2012","unstructured":"Clarke JL (2012) Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn) 18:328\u2013342. https:\/\/doi.org\/10.1212\/01.CON.0000413661.58045.e7","journal-title":"Continuum (Minneap Minn)"},{"key":"10870_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/B978-0-12-811161-1.00013-X","volume":"149","author":"S Taillibert","year":"2018","unstructured":"Taillibert S, Chamberlain MC (2018) Leptomeningeal metastasis. Handb Clin Neurol 149:169\u2013204. https:\/\/doi.org\/10.1016\/B978-0-12-811161-1.00013-X","journal-title":"Handb Clin Neurol"},{"key":"10870_CR44","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1212\/WNL.0000000000012122","volume":"97","author":"V Nersesjan","year":"2021","unstructured":"Nersesjan V, McWilliam O, Krarup L-H, Kondziella D (2021) Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review. Neurology 97:e191\u2013e202. https:\/\/doi.org\/10.1212\/WNL.0000000000012122","journal-title":"Neurology"},{"key":"10870_CR45","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s00415-020-09940-y","volume":"267","author":"N Mongay-Ochoa","year":"2020","unstructured":"Mongay-Ochoa N, Vogrig A, Mu\u00f1iz-Castrillo S, Honnorat J (2020) Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment. J Neurol 267:2154\u20132156. https:\/\/doi.org\/10.1007\/s00415-020-09940-y","journal-title":"J Neurol"},{"key":"10870_CR46","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","volume":"78","author":"R Velasco","year":"2021","unstructured":"Velasco R, Villagr\u00e1n M, Jov\u00e9 M et al (2021) Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol 78:864\u2013873. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0249","journal-title":"JAMA Neurol"},{"key":"10870_CR47","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000883","author":"J H\u00e9bert","year":"2020","unstructured":"H\u00e9bert J, Riche B, Vogrig A et al (2020) Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000883","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10870_CR48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00415-019-09544-1","volume":"267","author":"A Vogrig","year":"2020","unstructured":"Vogrig A, Gigli GL, Segatti S et al (2020) Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol 267:26\u201335. https:\/\/doi.org\/10.1007\/s00415-019-09544-1","journal-title":"J Neurol"},{"key":"10870_CR49","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00415-018-9143-x","volume":"266","author":"A Vogrig","year":"2019","unstructured":"Vogrig A, Joubert B, Maureille A et al (2019) Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. J Neurol 266:398\u2013410. https:\/\/doi.org\/10.1007\/s00415-018-9143-x","journal-title":"J Neurol"},{"key":"10870_CR50","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","volume":"124","author":"F Graus","year":"2001","unstructured":"Graus F (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124:1138\u20131148. https:\/\/doi.org\/10.1093\/brain\/124.6.1138","journal-title":"Brain"},{"key":"10870_CR51","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/brain\/awh203","volume":"127","author":"J Dalmau","year":"2004","unstructured":"Dalmau J (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127:1831\u20131844. https:\/\/doi.org\/10.1093\/brain\/awh203","journal-title":"Brain"},{"key":"10870_CR52","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jjco\/hyz087","volume":"49","author":"R Shibaki","year":"2019","unstructured":"Shibaki R, Murakami S, Oki K, Ohe Y (2019) Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient. Jpn J Clin Oncol 49:793\u2013794. https:\/\/doi.org\/10.1093\/jjco\/hyz087","journal-title":"Jpn J Clin Oncol"},{"key":"10870_CR53","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.cllc.2018.04.009","volume":"19","author":"H Matsuoka","year":"2018","unstructured":"Matsuoka H, Kimura H, Koba H et al (2018) Nivolumab-induced limbic encephalitis with anti-hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer 19:e597\u2013e599. https:\/\/doi.org\/10.1016\/j.cllc.2018.04.009","journal-title":"Clin Lung Cancer"},{"key":"10870_CR54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1634\/theoncologist.2017-0344","volume":"23","author":"KP Papadopoulos","year":"2018","unstructured":"Papadopoulos KP, Romero RS, Gonzalez G et al (2018) Anti-hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 23:118\u2013120. https:\/\/doi.org\/10.1634\/theoncologist.2017-0344","journal-title":"Oncologist"},{"key":"10870_CR55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-021-03695-w","volume":"152","author":"SL Duong","year":"2021","unstructured":"Duong SL, Barbiero FJ, Nowak RJ, Baehring JM (2021) Neurotoxicities associated with immune checkpoint inhibitor therapy. J Neurooncol 152:265\u2013277. https:\/\/doi.org\/10.1007\/s11060-021-03695-w","journal-title":"J Neurooncol"},{"key":"10870_CR56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","volume":"42","author":"JH Kang","year":"2021","unstructured":"Kang JH, Bluestone JA, Young A (2021) Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines. Trends Immunol 42:293\u2013311. https:\/\/doi.org\/10.1016\/j.it.2021.02.006","journal-title":"Trends Immunol"},{"key":"10870_CR57","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot JM, Voisin AL et al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5:1310. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1022","journal-title":"JAMA Oncol"},{"key":"10870_CR58","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6:865\u2013871. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"},{"key":"10870_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001622","volume":"8","author":"M Allouchery","year":"2020","unstructured":"Allouchery M, Lombard T, Martin M et al (2020) Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u2265 2 immune-related adverse events in patients with cancer. J Immunother Cancer 8:e001622. https:\/\/doi.org\/10.1136\/jitc-2020-001622","journal-title":"J Immunother Cancer"},{"key":"10870_CR60","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","volume":"152","author":"T Mikami","year":"2021","unstructured":"Mikami T, Liaw B, Asada M et al (2021) Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol 152:135\u2013144. https:\/\/doi.org\/10.1007\/s11060-020-03687-2","journal-title":"J Neurooncol"},{"key":"10870_CR61","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1212\/WNL.0b013e318271f87e","volume":"79","author":"X Chen","year":"2012","unstructured":"Chen X, Schwartz GK, DeAngelis LM et al (2012) Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. Neurology 79:1929\u20131931. https:\/\/doi.org\/10.1212\/WNL.0b013e318271f87e","journal-title":"Neurology"},{"key":"10870_CR62","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11154-016-9357-0","volume":"17","author":"A Sindoni","year":"2016","unstructured":"Sindoni A, Rodolico C, Pappalardo MA et al (2016) Hypothyroid myopathy: a peculiar clinical presentation of thyroid failure. Review of the literature. Rev Endocr Metab Disord 17:499\u2013519. https:\/\/doi.org\/10.1007\/s11154-016-9357-0","journal-title":"Rev Endocr Metab Disord"},{"key":"10870_CR63","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1634\/theoncologist.2014-0149","volume":"20","author":"S Singer","year":"2015","unstructured":"Singer S, Grommes C, Reiner AS et al (2015) Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist 20:806\u2013811. https:\/\/doi.org\/10.1634\/theoncologist.2014-0149","journal-title":"Oncologist"},{"key":"10870_CR64","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1001\/jama.2016.13658","volume":"316","author":"A Vogrig","year":"2016","unstructured":"Vogrig A, Zanoni T, Moretto G (2016) Nystagmus and lower extremity hyperalgesia after colectomy. JAMA 316:1488\u20131489. https:\/\/doi.org\/10.1001\/jama.2016.13658","journal-title":"JAMA"},{"key":"10870_CR65","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s13311-016-0433-7","volume":"13","author":"MJ Bradshaw","year":"2016","unstructured":"Bradshaw MJ, Venkatesan A (2016) Herpes simplex virus-1 encephalitis in adults: pathophysiology, diagnosis, and management. Neurotherapeutics 13:493\u2013508. https:\/\/doi.org\/10.1007\/s13311-016-0433-7","journal-title":"Neurotherapeutics"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10870-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10870-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10870-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T02:33:25Z","timestamp":1645151605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10870-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10870"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10870-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Vogrig reports receiving a fellowship grant from the European Academy of Neurology (EAN). No other disclosures were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}